Invest in China With Valeant Pharmaceutical Intl Inc.

China’s middle class is growing, expanding the market for Valeant Pharmaceuticals International Inc.’s (TSX:VRX)(NYSE:VRX) products.

Valeant Pharmaceuticals International Inc. (TSX:VRX)(NYSE:VRX) has been very quiet since it failed to acquire Botox-maker Allergan, Inc. It was announced on November 17 that Allergan had agreed to be acquired by Actavis plc. Since then, Valeant’s shares have grown by over $46 a share.

Investors are clearly happy with where the company is headed. And they should be, because Valeant has a unique business model that allows it to grow without spending tremendous amounts of money on R&D.

Buy rather than research

Over the past few years, Valeant has focused on buying companies rather than investing in new drugs. In many cases, the creation of a single drug from concept to commercialization can cost $1 billion. What’s really dangerous about that is many drugs go through many stages of investment and then are rejected by health agencies. That’s a lot of money spent without anything to show for it.

Valeant would rather buy companies that have products already well into development. Valeant then cuts research and development on fringe products, synergizes the sales forces, and streamlines the overall business. If a company has 10 products in the pipeline, Valeant may slash five because they are too far away from commercialization.

Many argue that this is bad because no research means the company can’t grow organically. The CEO of Valeant disagrees with this claim, arguing that many of its products are grown from within and that it just doesn’t throw money at the wall hoping it will stick.

China is its future

The types of products that Valeant creates are targeted toward the middle class. It’s advertising during the Super Bowl for a foot fungus treatment. It creates a lot of ophthalmological products. These are examples of products that people who have spare money can think about.

And China is getting to the point where its people are starting to join this middle class. Thanks to its acquisition of Bausch & Lomb, Valeant now has a strong foothold in China. When the Chinese start to think about buying contacts, Valeant will be in a prime position to supply these products to them. Other pharmaceutical companies don’t have the type of stronghold that Valeant has, so they will struggle to gain market share.

In 2013, China saw a 25% increase in contact lens usage. With a population over 1 billion, there is still plenty of room for Valeant to grow in Asia.

Some concern

There is some concern, though, about Valeant. Its P/E of 108.69 is astronomical. Further, it does not pay any dividends to investors. And finally, it has a lot of debt on its books. Fortunately, the company is focusing on paying its debt down, so it won’t be making new acquisitions for at least a few months.

All in all, Valeant is a good company. It’s rewarded investors with an incredible increase in share price. However, if you are looking to generate dividends, it’s not the company for you. Instead, you might want to check out our report on three really great dividend paying companies.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

man calculates finances
Dividend Stocks

What $50,000 Across 3 Dividend Stocks Could Add to Your Retirement Budget

A utility, a pipeline and a railway show how $50,000 could start paying part of the retirement budget.

Read more »

House models and one with REIT real estate investment trust.
Investing

Canada’s Largest REIT Offers a 5.1% Yield Worth Loading Up On

Discover why Choice Properties REIT offers a safe yield, superior scale and steady rent growth for investors looking for Canadian…

Read more »

woman stares at chocolate layer cake
Dividend Stocks

Power Corporation vs. Great-West Lifeco: Which Dividend Stock Would I Own?

Power Corporation gives you exposure to Great-West and more. I’d take Great-West directly when I want to know what’s funding…

Read more »

frustrated shopper at grocery store
Tech Stocks

Shopify Stock Is Down 16% in the Past Month: Should You Buy the Dip?

Shopify stock fell 16% recently. Discover the impact of interest rate hikes and market sentiment on Shopify's performance.

Read more »

hot air balloon in a blue sky
Bank Stocks

Hot Take: This Is the Top Canadian Dividend Stock for Safety and Growth

Here's a safe Canadian dividend stock for investors seeking reliable income, financial stability, and long-term growth.

Read more »

dividend growth for passive income
Energy Stocks

Enbridge Has a New CEO and 31 Straight Dividend Hikes: Worth Buying?

With a new CEO taking charge, 31 consecutive annual dividend increases, and a $38 billion growth backlog, Enbridge could be…

Read more »

a person watches a downward arrow crash through the floor
Dividend Stocks

Down Day, Wish List Ready: 3 Canadian Stocks to Keep Handy If You Have Cash to Invest

Market swings can catch you off guard, but be ready to take advantage of buying opportunities in a down day.

Read more »

View of high rise corporate buildings in the financial district of Toronto, Canada
Stocks for Beginners

Stantec Stock: Turning Infrastructure Spending Into a Long-Term Investment Case

A bigger infrastructure budget makes a good headline. Stantec’s backlog and earnings tell me whether shareholders are starting to benefit.

Read more »